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AN INVESTIGATION OF GENETIC VARIANTS IN CORTICOTROPH 
ADENOMAS 
LAUREN JOHNSON 
ABSTRACT 
Pituitary adenomas constitute about 15% of intracranial tumors, and about one-
third of secretory pituitary adenomas produce ACTH. Corticotroph adenomas, a 
subset of pituitary adenomas staining positive for ACTH, are further categorized 
into functional (FCA) and silent (SCA) adenomas. FCAs result in central 
Cushing’s disease (CD) due to the resulting excess of cortisol secretion 
stimulated by ACTH secretion through hormone disruption while SCAs exhibit 
mass effects and show increased aggression as compared to its functional 
counterpart. Obesity and cardiovascular disease, resulting from hypercortisolism 
in functional adenomas, increase patient morbidity while the invasive nature of 
silent adenomas increases mortality. Trans sphenoidal surgery (TSS) is the best 
available treatment option for cotricotroph adenomas, but tumor recurrence is 
common. We sought to identify differential genetic drivers of sporadic FCAs and 
SCAs in order to better characterize these tumors and develop novel treatment 
options. We examined 17 adenomas including 12 FCA and 5 SCA as well as 2 
corticotroph hyperplasia (CH) tissue samples. We performed next generation 
sequencing using OncoPanel versions 2 and 3 on patients operated on at 
Brigham and Woman’s Hospital between 2008 and 2018 and determined to have 
a corticotroph adenoma. 3 of 4 FCA patients screened for USP8 mutations 
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contained variants previously described in CD including USP8S718P and 
USP8S719del. 3 of the 12 FCA patients screened for mutations in ARID1B 
contained novel variants and 1 patient contained a variant previously described 
in large intestine adenocarcinomas. Additionally, SNPs were commonly identified 
in genes responsible for epigenetic regulation implicating histone modification as 
a therapeutic target. We identified recurrent copy number variants (CNV) in both 
FCAs and SCAs. Gains of 6p, 20q and 21q were frequently observed in FCAs 
alongside less common losses in 11p and 19q. Significant amplifications of 
chromosome 12 were detected in SCAs with single nucleotide deletions in 
chromosome 10. Furthermore, we report diverging genomic disruption between 
subtypes associated with functional hormone status. Our data identifies novel 
genetic drivers in subclasses of corticotroph adenomas and indicate distinct 
genomic profiles associated with hormone secretion and clinical presentation. 
Further research is required to better elucidate the role of these genetic variants 
and how they influence tumorigenesis and hormone production.  
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INTRODUCTION 
 
Pituitary tumors, the second most prevalent primary brain tumor, confers a 
variable clinical course1. In recent years there has been an increasing incidence 
rate of pituitary adenomas, likely attributable to a number of factors including 
improved detection methods and increased awareness amongst physicians2,3. 
Clinically significant tumors presenting with hormonal disturbances or mass 
effects must be precisely characterized to determine appropriate treatment and 
likely outcome4.  
Current classifications of pituitary adenomas are designated by cell 
lineage with further categorization into tumor subtypes. These subtypes are 
dependent on variations in hormonal content and immunohistochemical markers 
including pituitary transcription factors. Corticotroph adenomas, a subtype of 
pituitary tumors derived from the corticotroph cell lineage, present with t-box 
transcription factor (Tpit) expression and adrenocorticotrophic hormone (ACTH) 
positive immunohistochemistry. Because ultrastructural tumor characteristics can 
now be determined by immunohistochemistry, this method is required to make a 
definitive diagnosis. To identify corticotroph cell lineage, Periodic Acid-Schiff 
(PAS) is used to visualize ACTH secretory granules while reticulin stain 
accentuates acinar reticulin disruption, indicating a neoplasm5. 
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Functional Corticotroph Adenoma 
 
A functional subset of small corticotroph adenomas secrete ACTH at a 
nearly 2-fold increase in pulsatile amplitude as compared to baseline levels, 
resulting in persistently elevated plasma ACTH6. Chronic ACTH elevation from a 
pituitary lesion leads to excess adrenal glucocorticoid secretion resulting in 
Cushing’s disease (CD). Hypercortisolism induces central adiposity, myopathy, 
hyperglycemia, impaired reproductive function and psychiatric changes. Physical 
manifestations of CD include moon face, bruising, abdominal striae, buffalo 
hump, and hirsutism7. Moreover, cardiovascular weakness and an amplified 
propensity for infection are associated with increased morbidity and mortality in 
CD8,9.  
Diagnosing CD presents a challenge to physicians. Abnormal results in 
two of three biochemical tests are required to definitively diagnose 
hypercortisolism given the diurnal secretory rhythms of ACTH and cortisol. These 
assessments consist of a single low-dose (1 mg) dexamethasone suppression 
test (DST), two 24-hour urinary free cortisol (UFC) level tests, and two late night 
salivary cortisol (LNSC) level tests10. Additional testing is required to determine if 
hypercortisolism is ACTH-dependent, and whether the source of the ACTH is 
ectopic or from the pituitary gland. If magnetic resonance imaging (MRI) of a 
suspected pituitary lesion shows no significant findings, further biochemical tests 
or an inferior petrosal sinus sampling is necessary to confirm the source of 
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ACTH. Complete trans sphenoidal pituitary tumor resection (TSS) is the first-line 
treatment for CD. A follow up MRI is recommended 1-3 months following TSS to 
monitor recurrence11. Due to the small size of FCA, TSS is challenging for even 
experienced neurosurgeons. Tumor recurrence is common and remission rates 
remain low12. 
Somatic mutations in ubiquitin specific peptidase 8 (USP8) have been 
exclusively identified in FCAs13. Alterations in the deubiquitinase are more 
prevalent in females and correlate with smaller tumor size14. While plasma ACTH 
and cortisol levels are shown to be similar to patients with wild type USP8, 
proportionally more ACTH is produced relative to tumor size in USP8 mutated 
pituitary adenomas6. Additionally, USP8 mutant corticotroph adenomas recur 
more frequently and more quickly after TSS15. Mutations cluster in the 14-3-3 
protein binding motif between amino acids 713 and 720 and increase catalytic 
activity of USP8. Impaired 14-3-3 inhibitory protein binding results in augmented 
deubiquitinase activity and increased epidermal growth factor receptor (EGFR) 
activity9. Overexpression of EGFR in FCA induces POMC transcription resulting 
in amplified ACTH secretion15. Figure 1 illustrates the role of USP8 in ACTH 
production. 
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Figure 1. Signaling Pathway implicated in central CD.  
ACTH production pathway (shown in red boxes) within a pituitary corticotroph 
cell. The role USP8 plays in ACTH production is shown as well as commonly 
altered pathways resulting in pituitary adenomas. Those genes written in red 
were shown to be altered in FCAs in our study. 
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Silent Corticotroph Adenoma 
 
Silent corticotroph adenomas (SCA), a subdivision of corticotroph 
adenomas, are immunoreactive for ACTH but present as non-functioning pituitary 
macroadenomas (NFPA)16. Preoperatively, it is difficult to distinguish between 
NFPA and SCA as both have a mass effect that can result in headaches, 
hypopituitarism, and visual field defects. However, SCAs tend to have an earlier 
and more frequent recurrence than other NFPAs. Moreover, cavernous sinus 
invasion and intratumoral hemorrhage were more frequent in SCA17. The 2017 
WHO Classification of Pituitary Tumors identifies SCAs as high-risk due to their 
clinically aggressive behavior and recommends close postoperative monitoring5. 
As with FCAs, TSS is the recommended treatment for SCAs, but the invasive 
nature of these tumors prove to be challenging to surgeons12. 
Unlike FCAs, hypercortisolism does not manifest clinically or biochemically 
in SCA17. Many theories have been postulated as to why SCAs stain positively 
for ACTH but do not result in increased hormone secretion. While SCAs exhibit 
elevated proopiomelanocortin (POMC) levels similar to FCAs, the enzyme 
proprotein convertase 1 (PC1/3), required to cleave POMC into ACTH, is 
deficient in comparison. This deficit suggests posttranslational defects may 
attribute to the absence of hypercortisolism in SCAs18. Functional status may 
also be influenced by adenoma sensitivity to hypothalamic releasing hormones. 
Corticotrophin releasing hormone receptor 1 (CRHR1) and vasopressin V1b 
receptor (V1BR) mRNA expression levels have been shown to be downregulated 
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in SCA compared to FCA, while somatostatin receptors 1 and 2 (SSTR1, 
SSTR2) mRNA expression levels are upregulated. These results indicate FCAs 
have higher sensitivity to hypothalamic stimulants in comparison to SCAs, and 
SCAs have an increased sensitivity to hypothalamic inhibition. Furthermore, 
electron microscopy has revealed extensive lysosome and autophagy activity in 
SCAs implying lysosome dysfunction or abnormal ACTH synthesis drives the 
destruction of ACTH before it can be secreted in SCA cells16. 
 
Corticotroph Hyperplasia 
Corticotroph hyperplasia (CH), an ill-defined non-neoplastic pituitary 
lesion, is infrequently identified following TSS of a suspected FCA. In these 
instances, symptoms of hypercortisolism are present clinically and biochemically, 
but a nodular expansion of ACTH secreting acinar cells are present rather than 
an adenoma upon surgical intervention. It has been suggested that CH is 
associated with microadenoma formation, and may precede FCA formation19,20. 
Therefore, patients may continue to present with elevated ACTH and cortisol 
levels following surgical resection of a microadenoma due to multifocal CH21. 
Basal CH provides evidence for a continuum of FCA recurrence, emphasizing 
the importance of continued clinical and biochemical patient follow up22. Rarely, 
ectopic corticotropin-releasing hormone (CRH) secretion has been shown to 
induce pituitary CH leading to CD symptoms23. 
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Next Generation Sequencing 
With recent advancements in pituitary tumor detection, there has been an 
increased clinical demand for accurate and sensitive sequencing methods used 
to identify genomic variations and mutations24. Somatic diagnostic testing could 
be used to better identify tailored treatment options for patients and to create a 
genetic profile for pituitary adenoma subtypes. Next-Generation Sequencing 
(NGS) offers rapid and meticulous parallel-processing based on small amplicons 
which allows for more extensive tumor profiling25. Molecular stratification by copy 
number abnormalities, performed with NGS, has identified two unique molecular 
classes of pituitary tumors linking functional subtypes to level of genomic 
disruption. High levels of disruption were noted in the first class, associated with 
functional pituitary adenomas. The second class showed unique copy number 
losses or gains but were otherwise genomically quiet. Notably, SCAs showed 
higher disruption levels as compared to NFPAs. Therefore, genomic disruption 
as a clinically applicable criterion for patient stratification must be investigated 
further26.  
Using NGS to sequence solid tumors introduces certain challenges. Often, 
available DNA quantity is small due to limited sample size. Additionally, 
heterogeneity within tumor samples require highly sensitive sequencing 
techniques to accurately report sparse low-level mutations. Neoplastic samples 
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in particular may have variable necrotic and stromal content making purity and 
testing suitability difficult to deduce. Solid tumors are also prone to harsh or 
under fixation, facilitating DNA degradation and furthering complications25. 
Formalin-fixed, paraffin-embedded (FFPE) tissues are notably problematic, 
having a higher chance of chemical modification and DNA fragmentation. Under 
appropriate conditions, NGS has been shown to provide reliable and precise 
genomic data using FFPE samples27.  
OncoPanel version 3, an NGS based platform instituted in October of 
2016 by Dana-Farber, efficiently and accurately identifies variations in 447 
oncogenes and is capable of discovering novel somatic variants in the genome of 
solid tumor, blood or bone marrow samples. The assay also detects copy 
number variations, rearrangement, and structural modifications in fresh, frozen or 
FFPE tissue DNA28. A variety of genetic alterations across unselected tumor 
cohorts are detected using OncoPanel with high sensitivity and specificity for use 
in clinic29,30.  
Variants are appraised against background germline mutations, altered 
during development and present in the genetic code of all or most of a subject’s 
cells. Somatic single nucleotide polymorphisms (SNP) significantly present above 
baseline variants are identified for each gene assayed in the panel. Copy number 
variants (CNV), examining chromosome region gain or loss, are screened across 
the entire genome, not just within the genes being assayed for SNPs. Results 
from OncoPanel sequencing provide predictive and prognostic data regarding 
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pituitary tumors, enabling patient stratification for targeted therapies28,31. Genetic 
alterations are classified on a Tier system:  
 
Tier 1: The alteration has well-established published evidence 
confirming clinical utility in this tumor type, in at least one of the 
following contexts: predicting response to treatment with an FDA-
approved therapy; assessing prognosis; establishing a definitive 
diagnosis; or conferring an inherited increased risk of cancer to this 
patient and family. 
 
Tier 2: The alteration may have clinical utility in at least one of the 
following contexts: selection of an investigational therapy in clinical 
trials for this cancer type; limited evidence of prognostic association; 
supportive of a specific diagnosis; proven association of response to 
treatment with an FDA-approved therapy in a different type of cancer; 
or similar to a different mutation with a proven association with 
response to treatment with an FDA-approved therapy in this type of 
cancer. 
 
Tier 3: The alteration is of uncertain clinical utility, but may have a 
role as suggested by at least one of the following: demonstration of 
association with response to treatment in this cancer type in 
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preclinical studies (e.g., in vitro studies or animal models); alteration 
in a biochemical pathway that has other known, therapeutically-
targetable alterations; alteration in a highly conserved region of the 
protein predicted, in silico, to alter protein function; or selection of an 
investigational therapy for a different cancer type. 
 
Tier 4: The alteration is novel or its significance has not been studied 
in cancer. 
 
Tier 5: The alteration has been determined to have no clinical utility, 
either for selecting therapy, assessing prognosis, establishing a 
diagnosis, or determining hereditary disease risk28. 
 
OncoMap 4, a high throughput genotyping assay introduced in 2011, 
screened 41 cancer related genes and was only capable of identifying known 
mutations at 471 different loci. This initial version did not classify mutations on a 
tier system. The next version of OncoPanel v2 was released in 2013 and was 
capable of detecting somatic mutations in 300 oncogenes using massively 
parallel screening. Additionally, the updated version was capable of identifying 
structural variants and copy number changes32. Similar to the most recent 
OncoPanel, OncoPanel v2 showed high precision and sensitivity for base 
substitutions, copy number alterations and indels, making it suitable for clinical 
use31. Of note, USP8 was not screened in these initial assays. 
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Genetic Variants Associated with Pituitary Adenomas 
Analysis of recurrent mutations in pituitary adenomas using OncoPanel 
found significant alterations in three pathways regulating cell cycle, DNA damage 
response and transcriptional regulation as well as variability in copy number, 
supported by previous screenings1,26. Although recurrent somatic single 
nucleotide variants in sporadic pituitary adenomas are infrequent, Bi et. al, 2017, 
performed using OncoPanel v2, identified eight significantly altered genes. Of 
these genes, those required for DNA damage response included ATM, BRCA1, 
BRCA2, PRKDC, and FANCA variants. Mutations in damage response genes 
have been further implicated in tumorigenesis for a number of cancers. Genetic 
alterations within genes involved in cell cycle regulation were also identified by 
the study and included SNPs of NOTCH1/2, PIK3CA, and GLI1/2/3. Furthermore, 
recurrent mutations in chromatin-modifying genes 
ARID1A, ARID1B, ASXL1, BRD4, and CREBBP were recognized alongside 
alterations in T-cell signaling and immune response genes1. Familial pituitary 
adenomas are linked to a different genetic profile with mutations identified in AIP, 
CDKN1B, GPR101, MEN1, PRKAR1A and SDHx33. These genetic alterations 
often present with earlier adenoma onset, more aggressive tumor behavior, and 
treatment resistance34. FCAs in particular is associated with a mutation in USP8, 
although corticotroph adenomas tend to vary greatly in single nucleotide 
alteration occurrence17. Increased GPR101 expression and loss of CABLES1 
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may also be implicated in corticotroph adenoma formation through upregulation 
of the EGFR pathway and decreased expression of cell cycle regulator p27, 
respectively35.  
Pituitary adenomas have been shown to acquire recurrent somatic CNVs 
resulting in genomic disruption1,26. Degree of disruption is correlated with tumor 
functionality and subtype. Non-functional adenomas are typically associated with 
lower levels of disruption while functional adenomas are more disrupted, trending 
toward a higher incidence of lymph node metastases; however, this pattern of 
disruption is not seen in SCAs26. Interestingly, SCAs and FCAs have displayed 
comparable levels of genomic disruption while disruption in SCAs was more 
significant than in other NFPAs36. Significant chromosomal losses of 1p and 11 
were shown to be the most common genetic alteration found in pituitary tumors 
across all classifications, followed by losses in chromosomes 1q, 2 and 181,26. 
Additionally, chromosomes 4, 7, 10, 12, 14 and 15 were altered to a less frequent 
extent26.  
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METHODS 
 
A list of patients undergoing transnasal transsphenoidal (TSS) surgery for 
suspected pituitary lesions at Brigham and Women’s Hospital (BWH) between 
2008 and 2018 was compiled by an attending neurosurgeon. Diffuse ACTH 
immunohistochemical staining of tissue samples and pre-operative clinical 
diagnoses further identified 135 patients with likely corticotroph lesions. Of these, 
31 were excluded from the cohort for the following reasons: inadequate available 
data, non-trans sphenoidal lesion removal, the presence of an ectopic ACTH 
tumor, a patient history of bilateral adrenalectomy, surgical intervention 
performed at an outside hospital, incorrect corticotroph classification, and 
discrepancy between immunostaining results and clinical suspicion of functional 
corticotroph adenomas. 
Diagnoses of the remaining 104 cases were confirmed by an experienced 
neuropathologist. A functional adenoma classification required biochemical and 
clinical evidence of ACTH-dependent hypercortisolemia with an ACTH staining 
lesion. Patients with ACTH positive lesions and no evidence of hypercortisolemia 
were classified as SCA. Those clinically suspected of FCA with a nondelineated 
lesion consisting of ACTH staining cells and abnormally expanded acini were 
classified as corticotroph hyperplasia. Reticulin staining was used to confirm the 
diagnosis of hyperplasia. Informed consent was obtained from the patients for 
genetic testing. 
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OncoPanel and OncoMap assays were performed for subjects with 
eligible samples including freshly frozen tissue, formalin-fixed paraffin-embedded 
(FFPE) tissue sections, and fresh peripheral blood. An anatomic pathologist 
estimated tumor content and identified samples with at least 20% malignant cells 
for OncoPanel versions 2 and 3 and 50% malignant cells for OncoMap using cell 
count with flow cytometry for fresh blood. Tissue sections of adequate cancer 
measuring at least 3 mm in linear dimension were screened. DNA was isolated 
from 24 samples using a solution-phase Agilent SureSelect hybrid capture kit. 
Sequencing was performed using Illumina HiSeq 2500 sequencer.  
Samples containing 50% tumor nuclei sequenced by OncoMap between 
2010 and 2012 analyzed 41 cancer genes at 471 loci. Those assays performed 
between the years 2013 and September 2016 surveyed sequences of 300 
cancer genes while rearrangement detection was analyzed in 113 introns across 
35 genes. Following October 2016, the OncoPanel version 3 assay analyzed 447 
genes including rearrangement of 191 regions across 60 cancer genes. Copy 
number variants (CNV) were identified throughout the genome for both versions 
of OncoPanel but not for OncoMap. See Appendix 1 for full list of assayed genes. 
OncoPanel or OncoMap data was available for 24 subjects within the 
previously established cohort. Of these 24 patients, 20 were shown to have a 
successful screen with clinically relevant data. 6 of 12 FCAs were screened with 
OncoPanel version 2 while 3 of 5 SCAs were screened with this version. 6 FCAs 
and 2 SCAs were assayed with OncoPanel version 3. 1 of 2 CH subjects was 
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screened with OncoPanel version 2 and the other with OncoPanel version 3. An 
apoplectic adenoma, screened with OncoPanel version 2, was disregarded due 
to lacking diagnostic evidence. Genes with single nucleotide polymorphisms 
(SNP), including insertions or deletions, were analyzed separately from those 
with copy number variations. Genes with a significant frequency of SNP 
recurrence in each subgroup were identified using a Z-test. A Wilcoxon rank-sum 
test was performed for distribution comparisons to determine genomic disruption 
between subtypes using R. The same method was repeated to analyze CNVs. A 
Student’s t-test was performed using R to compare copy number gain and loss 
between subtypes (R Core Team, 2013). SNPs and CNVs considered significant 
(P ≤ 0.05) after analysis were subject to a literature review.  
Variants identified in genes of significant recurrence were analyzed using 
Panther and Poly-Phen-2. SNPs were classified based on evolutionary 
preservation of a specific genetic position as being probably damaging (time > 
450 million years), possibly damaging (450 million years > time > 200 million 
years), and probably benign (time < 200 million years). SNPs were also 
categorized as benign, possibly damaging, and probably damaging using 
comparative and physical considerations including sequence-based and 
structural features of a protein. 
The Institutional Review Board of Brigham and Women’s Hospital 
approved this study.  
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RESULTS 
 
Study Cohort 
The final cohort was stratified into three groups: FCA (n=12), SCA (n=5), 
and CH (n=2). One subject with an uncategorized apoplectic adenoma was 
excluded from the final group. An average of 6 SNPs were detected per subject 
within the cohort (range: 0 --15, n=19). Of the 19 samples, 95% harbored a single 
nucleotide polymorphism (SNP) in more than one assayed gene. SNP mutational 
load was not significantly different between any of the three groups; however, 
FCA and SCA polymorphism frequency distributions were shown to be 
significantly different, with a higher frequency distribution seen in FCAs 
(p=2.91E-15). 
Of the 447 genes analyzed by the latest version of OncoPanel, 94 genes 
were observed to have a SNP. OncoPanel version 3 was used to screen 47.4% 
(9 of 19) of samples, in which we identified 16 genes not analyzed by OncoPanel 
version 2 (Appendix 1). This suggests a higher variant frequency of those genes 
not screened in OncoPanel version 2 than is represented in our data. 
CNVs were present in 76.5% (13 of 17) of all adenomas within our cohort 
and in 66.7% (8 of 12) of FCAs. All silent corticotroph adenomas contained CNVs 
while no CNVs were detected in CH. Examining levels of chromosomal CNVs, 
we found SCA genomes to be significantly more disrupted than FCAs (p=4.42E-
108, see Figure 2). Functional corticotroph adenomas showed a significantly 
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higher mean of copy number gains as compared to SCA samples (p=0.0044), but 
not of copy number losses. Our data corroborates the results seen in Bi et. al, 
2017, in which SCAs had highly disrupted genomes while NFPAs had lower 
disruption levels than functional pituitary adenomas in most other subtypes26. 
Interestingly, those FCA samples containing a single point mutation in USP8 
were less disrupted than samples without this mutation, while both sample sets 
had a quieter genomic profile than the majority of SCA samples (see Figure 2). 
Corticotroph hyperplasia showed similar genomic disruption to FCAs with a 
mutation in USP8. No CNVs were identified in either CH subject, but one subject 
contained a intronic deletion (breakpoints 5:179239238, 5:179239239). 
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Figure 2: Representative plot of copy number variations taken from 
OncoPanel version 3 analysis. 
(a) SCA subject illustrating a disruptive genomic profile. Log-fold change (LFC) 
in read count, -1 is equal to one less copy number and 0.58 is a one copy gain 
across all chromosomes, excluding sex chromosomes (b) FCA subject 
containing a single point mutation in USP8 illustrating a quite genomic profile. 
(c) FCA subject without mutation in USP8. (d) CH subject with a quiet genomic 
profile.  
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Chromosomal rearrangements were identified in 25% (3 of 12) of FCAs, although 
no region of significance was apparent. No rearrangements or structural breaks 
were found in any of our 5 silent corticotroph adenomas; however, OncoPanel 
detected an intronic deletion in one of our two hyperplasia subjects. 
 
Recurrent Single Nucleotide Polymorphisms 
We identified two genes demonstrating a significant frequency of SNP 
recurrence. No significantly recurrent mutated genes were identified in either 
SCA or CH subgroups. USP8, a previously validated oncogenic driver of CD, 
was not included in the OncoPanel version 2 assay, and recurred in 66.7% (4 of 
6) of FCA samples screened with OncoPanel version 3. USP8 was not altered in 
SCA or CH samples (p=3.55E-08). Previously described variations of USP8 
(USP8S718P and USP8S719del) primarily affected the 14-3-3 binding motif, 
consistent with preceding literature indicating a gain of function mutation in 
patients with CD.  
ARID1B was altered in 25.0% (3 of 14) of FCAs (p=0.0027). This gene 
plays a role in chromatin remodeling by stabilizing the switch/sucrose non-
fermentable (SWI/SNF) nucleosome remodeling complex and has been 
implicated as a cause component of isolated agenesis of the corpus callosum 
anomalies in patients with genetic disabilities37,38. The mRNA of this gene is 
expressed throughout the brain, including the pituitary gland39. Although 3 of the 
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4 variants of ARID1B identified in our study were of unknown significance, 
ARID1BA931T has been described in large intestine adenocarcinoma40. The 
subject containing this variant had an additional mutation in homolog ARID1A, a 
co-mutation often described in a number of cancers. Deficiency in both results in 
functional dependence and cooperative cancer promotion38. Missense variants 
ARID1BM1248V and ARID1BA931T were determined to be possibly damaging to 
protein and cellular function when taking into consideration evolutionary 
preservation of the gene. When examining sequence and structural components 
of the gene, both mutations were classified as benign; although, as stated 
ARID1BA931T has been shown to produce a carcinogenic outcome. 
ARID1BA248_G249insGG and ARID1BF55_Q56insQ resulted in frameshift mutations early 
in the genetic code. The implications of these alterations include loss of protein 
function and disrupted cellular operation. As previously stated, loss of ARID1B 
function results in the destabilization of SWI/SNF nucleosome remodeling 
complex, preventing the restructuring of DNA. Of interest, low copy number gains 
of additional SWI/SNF complex subunits, including ARID1A, ARID1B and ARID2 
as well as SMARCA4 and SMARCB1 were identified exclusively in silent 
corticotroph adenomas and were not found in FCAs.  
We found thirteen recurrent genes with an insertion, deletion or missense 
mutation in more than one subject without significance (p>0.05). These genes 
are involved in three major cellular pathways: chromatin remodeling and 
transcriptional modification; DNA damage repair; and cell cycle regulation, 
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differentiation and maturation. Mutations in chromatin modification genes are 
implicated in a wide variety of tumors. Within our cohort we identified variants in 
ARID1A, CREBBP, EP300, and KAT6A with no discernable pattern of 
recurrence. Of note, KAT6A was only included for analysis in OncoPanel version 
3. While Bi et. al, 2017 implicated ASXL1 and BRD4 in pituitary adenoma 
tumorigenesis, these genes were not altered in our cohort. The cell cycle 
pathway contained SNPs in FBXW7, NF2, NOTCH1 and NOTCH2. NOTCH1 
was exclusively altered in FCAs. Non-recurrent SNPs in GLI1 and PIK3CA, 
suggested to play a role in cell cycle dysfunction in sporadic pituitary adenomas, 
were identified in two separate FCA subjects. Additionally, we identified 
mutations in the DNA damage response pathway, particularly in ATM, BRCA2, 
and PRKDC, paralleling the aforementioned study. Both ATM and BRCA2 
showed recurrent SNPs in FCA samples only.  
Cellular readings determined the composition of cells containing a specific 
variant within the tumor sample. A higher percentage of cells containing the 
variant of interest implicated the variant as a germline mutation. Readings below 
60% were considered somatic and thus likely tumor drivers. Those variants with 
readings in less than 30% of the sample cell populations were considered 
pathogenic mutations. Most of these mutations were frameshift altering the gene 
of interest drastically; however, a missense mutation of PRKDCR70L was identified 
as the lowest reading of recurrent genes. A summary of recurrent nucleotide 
polymorphisms and their frequency are included in Table 1.  
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Table 1: Recurrent somatic polymorphisms categorized by function. 
Table of recurrently mutated genes organized by functional role within the cell. 
The frequency of alteration for each gene within the entire adenoma population is 
included (n=17), excluding CH subjects. Polymorphisms identified in each subject 
are listed alongside the associated protein change. The percentage of cells 
within the sample containing the accompanying polymorphism are listed as the 
cellular percentage. 
 
Epigenetic Regulation 
Gene Frequency Variant Protein Cellular Percentage 
ARID1A 11.8% 
c. 6458G>A p.N2220S 48% of 279 reads  
c. 6659A>G p.R2153H 50% of 446 reads  
ARID1B 23.5% 
c. 3742A>G p.M1248V 48% of 168 reads  
c. 744_755insGGCGGC p.A248_G249insGG 22% of 367 reads  
c. 2791G>A p.A931T 51% of 307 reads  
c. 165_166insCAG p.F55_Q56insQ 57% of 14 reads  
CREBBP 11.8% 
c. 1655C>A p.P552Q 42% of 239 reads  
c. 5264G>A p.S1755N 47% of 114 reads  
EP300 11.8% 
c. 6567_6568delGCAACAGCAGCA p.Q2190_Q2193del 9% of 220 reads  
c. 5728_5730delCCT p.P1910del 41% of 339 reads 
KAT6A 11.8% 
c. 1185T>G p.D395E 13% of 623 reads  
c. 4145C>T p.T1382M 47% of 900 reads  
Cell Cycle Regulation 
FBXW7 11.8% 
c. 501+28986C>A UKN 46% of 367 reads 
c. 934A>T p. R312* 58% of 179 reads 
NF2 11.8% 
c. 590G>T p. G197V 49% of 185 reads 
c. 1765G>A p. V589M 43% of 506 reads  
NOTCH1 11.8% 
c. 4426 G>A p.G1476S 52% of 304 reads 
c. 7046C>T p.P2349L 59% of 27 reads  
NOTCH2 17.6% 
c. 5054C>G p.A2366V 48% of 522 reads  
c. 7097C>T p.A1685G 45% of 416 reads 
UKN UKN 85% of 60 reads  
DNA Damage Response 
ATM 11.8% 
c. 7875T>G p.D2625E 46% of 357 reads  
c. 7876G>C  p.A2626P 46% of 358 reads  
c.3118A>G p.M1040V 42% of 293 reads 
BRCA2 11.8% 
c. 5202A>T p.E1734D 47% of 609 reads  
c. 1786G>C p.D596H 50% of 287 reads  
PRKDC 11.8% 
c. 209G>T p. R70L 6% of 94 reads 
c. 7691T>G p. M2564R 63% of 557 reads 
USP8 23.5% 
c. 2151_2153delCTC p. S719del 38% of 409 reads  
c. 2151_2153delCTC p. S719del 15% of 290 reads  
c. 2152T>C p. S718P 40% of 350 reads  
c. 2153_2167delCCTCCCCAGATATAA p. S719_T723del 29% of 710 reads 
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Unexpectedly, SNPs were not found in BRCA1 and FANCA. AIP, 
CDKN1B, GPR101, PRKAR1A, MEN1 and SDHx. Genes implicated in familial 
pituitary adenoma formation were unaltered by missense or frameshift mutations 
in our sample population; however, CNVs in CDKN1B, PRKAR1A, MEN1 and 
SDHx were present. CABLES1 was not assayed in either OncoPanel version 2 
or 3, but this gene has been reported to be altered in sporadic corticotroph 
adenomas35.  
Of all SNPs identified within our corticotroph adenoma population, 25.3% 
(20 of 79) occurred in those genes coding for epigenetic regulators. SNPs in 
histone modifying genes were most common, accounting for 90.0% (18 of 20) of 
epigenetic regulators or 22.9% (18 of 79) of all identified SNPs. Within this 
subgroup of epigenetic regulators, 33.3% (6 of 18) encoded proteins responsible 
for histone acetylation, 22.2% (4 of 18) encoded proteins responsible for histone 
phosphorylation, 27.8% (5 of 18) effected histone methylation and 5.6% (1 of 18) 
were responsible for histone ubiquitination. ARID1B was the only altered 
epigenetic regulator responsible for ubiquitination of a histone, lending enzymatic 
function to the SWI/SNF nucleosome remodeling complex41. The remaining 9.5% 
(2 of 21) of SNPs involved in epigenetic regulation were identified in genes 
encoding chromatin remodeling proteins.  
Within our SCA subjects, 21.7% (5 of 23) of SNPs were found in 
epigenetic regulating genes, 80% (4 of 5) of those genes were involved in 
histone modification and 75% (3 of 4) of histone modifying SNPs were implicated 
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in histone acetylation. 30.0% (18 of 60) of SNPs in FCAs affected epigenetic 
regulators and of these 88.9% (16 of 18) were responsible for histone 
modification. 31.3% (5 of 16) of SNPs found in FCA histone modifying genes 
were involved in methylation, 25.0% (4 of 16) in acetylation, 25.0% (4 of 16) in 
phosphorylation and 6.3% in histone ubiquitination suggesting a larger role of 
methylation in FCAs. At least one epigenetic SNP was found in 88.2% (15 of 17) 
of adenoma subjects and 58.8% (10 of 17) had multiple SNPs in epigenetic 
regulation genes. Specific regulatory genes organized by method of epigenetic 
modulation can be seen in Table 2 while the frequency of altered epigenetic 
regulatory genes categorized by functional classification is summarized in Figure 
3.  
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Table 2: List of genes identified in corticotroph adenoma cohort and their 
role in epigenetic regulation. 
Epigenetic regulatory genes containing a SNP in at least one FCA or SCA 
subject categorized by gene function and further identified by modification 
method. Those with an asterisk (*) were found to be mutated in more than one 
subject. 
 
 
 
 
  
FCA 
Gene Function Modification 
ARID1A* Chromatin Remodeling - 
ARID1B* Histone Modification Ubiquitination 
ATM* Histone Modification Phosphorylation 
ATR Histone Modification Phosphorylation 
BRCA2* Histone Modification Acetylation 
CDK2 Histone Modification Phosphorylation 
CREBBP* Histone Modification Acetylation 
ERCC6 Chromatin Remodeling - 
KAT6A* Histone Modification Acetylation 
KAT6B Histone Modification Acetylation 
KDM5A Histone Modification Methylation 
KDM6A Histone Modification Methylation 
KMT2D Histone Modification Methylation 
NSD1 Histone Modification Methylation 
PBRM1 Histone Modification - 
PRDM1 Histone Modification Methylation 
PRKDC* Histone Modification Phosphorylation 
TP53BP1 Histone Modification - 
SCA 
Gene Function Modification 
EP300* Histone Modification Acetylation 
IKZF1 Chromatin Remodeling - 
KAT6A* Histone Modification Acetylation 
PRKDC* Histone Modification Phosphorylation 
TP53 Histone Modification Acetylation 
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Figure 3: Functional categorization of epigenetic regulatory gene 
single nucleotide polymorphisms. 
The chart illustrates the frequency of subjects, excluding CH, with at 
least one SNP in an epigenetic regulatory gene as well as the number 
of epigenetic genes altered in each functional group in comparison to 
all genes in the study containing an SNP (94) and the number of SNPs 
identified in each functional group in comparison to all SNPs in the 
study (117). 
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Recurrent Copy Number Alterations 
Losses in chromosomal locations 10p14, 10q11 and 11p13 were 
significantly recurrent in 29.4% (5 of 17) of samples across all adenoma 
subtypes. Losses of 10p14 and 10q11 have been linked to colorectal cancer and 
copy number loss of 10p14 is associated with hypoparathyroidism, deafness and 
renal dysplasia (HDR) syndrome42-44. 10q11 loss has been associated with a 
better prognosis and lower level of distant metastases in head and neck 
squamous cell carcinoma45. Furthermore, allelic loss of 11p13 has been found in 
follicular thyroid cancer and is the site of putative genes associated with multiple 
endocrine neoplasia Type 146. Those genes associated with significant 
chromosomal losses include GATA3 (10p14), RET (10q11), and WT1 (11p13). 
GATA3 and RET are associated with cell differentiation, while WT1 plays a 
particular role in in Wnt signaling during pituitary development47. This gene is 
associated with multiple neuroendocrine neoplasia Type 1(MEN1) while RET is 
well associated with multiple neuroendocrine neoplasia Type 2 (MEN2)48,49. 
Rarely, GATA3 is diffusely positive in corticotroph adenomas but is more 
positively associated with gonadotrophomas50.  
Copy number gains in 20q13 (41.2%, 7 of 17) and 21q22 (29.4%, 5 of 17) 
were the significant across subtypes, excluding CH. Low level copy number 
gains of 20q have frequently been identified in breast, colon, bladder and ovarian 
carcinomas and is correlated with overcoming cellular senescence51. 
Furthermore, amplification of 20q13 acts as a prognostic marker indicating faster 
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tumor progression and worse survival in these cancers52,53. Interestingly, allelic 
copy number gain of chromosomal region 21q22 is linked to Down syndrome54. 
Structural rearrangements of this area are associated with a poor prognosis in 
acute myeloid leukemia55,56. GNAS and U2AF1 were the most frequently 
amplified genes in chromosomal regions 20q13 and 21q22, respectively. Copy 
number gains of GNAS, a stimulatory G-protein important in signal transduction, 
were found in 4 FCA and 3 SCA subjects while gains in U2AF1, involved in post-
transcriptional mRNA modification, were found in 3 FCA and 2 SCA subjects. 
Epigenetic and genetic alterations in GNAS are the underlying molecular 
hallmark of GH-secreting tumors, including those resulting from McCune-Albright 
syndrome57. Activating mutations in GNASR201 have been identified in pituitary 
adenomas secreting growth hormone as well as CD in rare cases35,58. 
Interestingly, differential amplification of GNAS has been recognized in 
corticotroph adenomas, with upregulation of GNAS in FCA as compared to 
SCA59. Additionally, activating GNAS mutations have been implicated in 
prolactinomas as well as ectopic Cushing’s syndrome35,60.  
Variations in 6p21, found in 29.4% (5 of 17) of adenoma samples, were 
found to be significantly recurrent, although directional loss or gain was 
insignificant across subtypes. 6p21 low copy number gains were found in 17.7% 
(3 of 17) of adenomas while single copy deletions were only found in 11.8% (2 of 
17). Within this chromosomal region, CCND3, PIM1, CDKN1A, and FANCE 
showed significant copy number variation. CCND3, CDKN1A and FANCE play a 
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role in DNA damage repair as well as cell cycle progression. PIM1 targets 
misfolded or damaged proteins for degradation within the mitochondrial matrix. 
Interestingly, CDKN1A mutations are rare in pituitary adenomas; however, 
expression is often decreased in tumor tissue as compared to normal pituitary 
tissue from the same subject61. Copy number loss in the 6p21 region has been 
linked with nasopharyngeal carcinoma susceptibility while gain is associated with 
renal cell carcinoma and increased angiogenesis in endometrial cancer62-64. 
Notably, low copy number gains of 6p21 and 20q13 were significant in FCA but 
not SCA, present in 16.7% (2 of 12) and 33.3% (4 of 12) of FCA subjects, 
respectively (p=0.01). Regional copy number gains of 6p and 20q have been 
implicated in hormone secreting pituitary adenomas but not in silent pituitary 
adenomas65. Amplification of 21q22 was also significantly recurrent in 25.0% of 
FCAs (3 of 12), not SCAs (p=0.01). Recurrence of single copy deletions in 11p13 
(16.7%) and 19q13 (16.7%) were identified in FCA (2 of 12), while a low gain of 
19q13 was found in 1 FCA subject. Duplication of 19q13 is associated with GIP-
dependent Cushing’s syndrome and indicates a poor prognosis in diffuse large B 
cell lymphoma66,67. Additionally, gain in this region may be a genetic cause of 
intrauterine growth restriction68. Within chromosomal region 19q, AXL was found 
to be significantly reduced in 16.7% (2 of 12) of FCAs. WT1, found in region 
11p13, had copy number losses in 16.7% (2 of 12) of FCAs as well. As 
mentioned previously, this gene is implicated in MEN1 and also plays a role in 
Wilm’s tumor formation69,70. Copy number variations in 2q34, housing ERBB4, 
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were found in 16.7% (2 of 12) of FCA samples with no directional significance. 
This region is associated with neural development and function71,72. Both AXL 
and ERBB4 have roles in signal transduction and activation of the PI3K pathway. 
Table 3 summarizes the most significant CNVs identified in our total adenoma 
cohort and by subtype. See Appendix 2 for a full list of defined genes. 
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Table 3: Significant Copy Number Variants by Subtype. 
Table of significant copy number gains, indicated by green, and losses, indicated 
by red, categorized by adenoma subtype including the entire corticotroph 
adenoma cohort. No significantly recurrent CNVs were identified in CH. 
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Importantly, Axl-EGFR heterodimerization has been shown to induce 
cellular invasion in glioblastoma multiforme as well as modulate EGFR resistance 
in both lung and breast cancer. This suggests Axl may be a therapeutic target in 
cancers demonstrating resistance to EGFR targeted therapies71,73. Low copy 
number gains in EGFR were identified in 60.0% (3 of 5) of SCAs along with an 
AXL copy number gain in two of the same SCA subjects with EGFR CNVs. Loss 
of AXL expression, as seen in 16.7% (2 of 12) of FCA samples, results in 
upregulation of ERBB3 while amplification, seen in 40.0% (2 of 5) of SCA 
samples, increases cellular invasion of adenomas. Copy number gains in ERBB3 
were identified in 80.0% (4 of 5) SCA subjects and are similarly associated with 
increased tumor invasion74.  
Axl is responsible for phosphorylation of PTPN11 and thus regulation of 
the MAPK signaling pathway75. Our data identified recurrent copy number gains 
of PTPN11 in 60.0% of SCAs as well as one copy number loss in this subtype 
corresponding with AXL amplification. No PTPN11 CNVs were found in FCAs. 
Furthermore, the protein product of CBL, an E3 ubiquitin ligase found to be 
altered in our cohort, targets Axl for degradation during normal cellular 
functioning and is necessary for EGFR recycling76,17. Copy number losses of 
CBL and CBLB were found in 60.0% (3 of 5) and 20.0% (1 of 5) of SCA, while 
loss of CBL was found in 1 FCA. Our results imply that AXL signaling plays a 
significant role in tumorigenesis, in both SCA and FCA.  
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SCA samples showed a significant recurrence of copy number gains in 
chromosomal regions 12p12-13 and 12q12-15. Both regional amplifications were 
found in 80% of SCA subjects. A gain of 12p has been associated with a 
gemistocytic histology in astrocytomas and is implicated in testicular germ cell 
tumors77,78. Previous papers have found losses in 12p13.13 linked to FCAs; 
however, our findings identified a closer relationship between 12p13 and SCAs36. 
The region of 12p most frequently amplified in our SCA samples encompassed 
KRAS, CDKN1B, ETV6 and CCND2. CDKN1B, coding for p27, and CCND2, 
cyclin D2, are involved in cell cycle regulation. P27 prevents progression at the 
G1/S checkpoint of the cell cycle while cyclin D2 interacts with cyclin dependent 
kinases, including the protein product of CDK4, to progress the cell cycle into S 
phase. Additionally, KRAS and ETV6, an inhibitory transcription factor, plays 
important roles in cell signaling and can activate MAPK and PI3K pathways 
within the cell resulting in tumorigenesis79. Of interest, loss of CDKN1B function 
is a genetic cause of MEN4 syndrome with a similar phenotypic presentation to 
MEN1 syndrome. MEN4 syndrome is linked to sporadic somatotrophinoma 
growth while mutations in MEN1 suggest a predisposition to prolactinomas as 
well as nonfunctional pituitary adenomas35. There were no copy number losses 
of CDKN1B in our adenoma population; however, a connection may exist 
between amplification and SCA tumorigenesis. Moreover, within our cohort 4 
subjects contained single copy deletions of MEN1 (21.1%), 1 FCA subject (8.3%) 
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and 3 SCA subjects (60.0%), suggesting a weak correlation between the MEN1 
gene and nonfunctional corticotroph adenoma formation. 
Amplification of 12q12-15 has been heavily implicated in atypical and well-
differentiated liposarcomas as well as breast hamartomas80,81. Overexpression of 
genes located in the 12q13-15 have also been suggested to play a role in 
tumorigenesis in a small subset of neuroblastomas82. The genes most commonly 
amplified in regions 12q12-15 from our data were ARID2, ERBB3, KMT2D, 
STAT6, GLI1, CDK4, and MDM2. ERBB3 in particular has been associated with 
prolactinoma formation and increased prolactin secretion while studies have 
found overexpression of GLI1 in as much as 87% of their pituitary tumor 
cohort83,84. ARID2, a subunit of SWI/SNF nucleosome remodeling complex 
responsible for maintaining tissue specific gene expression, has been shown to 
interact through its complex with the protein products of CDK4 and CCND2 to 
promote cell cycle progression85,86. Moreover, MDM2 targets p53 for 
ubiquitination, which when amplified inhibits the adaptive biological functions of 
p53, and STAT6, a transcription activator, have been identified in many solid 
tumors87,88. Of less literature relevance, KMT2D has been shown to indicate a 
better prognosis in small cell lung carcinoma89. 
Copy number losses of 10p14 and 10q11, demonstrating considerable 
recurrence in our pituitary adenoma population, were significantly recurrent in 
80.0% (4 of 5) of SCA subjects as well. GATA3 and RET were again identified as 
genes of consequence in this region. Additionally, CNVs in chromosomal region 
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12q24 in were identified in 80.0% (4 of 5) of SCA samples. Of these samples, 
60.0% (3 of 5) had low copy number gains in 12q24 while 20.0% (1 of 5) had a 
single copy deletion of this area. Interestingly, allelic amplification of 12q24 is 
inversely correlated with hippocampal volume and participates in cognitive 
decline90. Conversely, copy number loss of 12q24 is linked to bipolar disorder as 
well as schizophrenia, likely containing other psychiatric risk variants91,92. Within 
this region, alterations in PTPN11, HNF1A and SH2B3 occurred with significant 
frequency in 80.0% (4 of 5) of SCAs. As mentioned previously, PTPN11 plays an 
important role in MAPK pathway regulation and is phosphorylated by AXL. 
HNF1A is a transcriptional activator, particularly required for expression of liver 
and pancreatic islet cell genes while SH2B3 inhibits cytokine signaling. Both 
HNF1A and SH2B3 function in insulin-dependent diabetes mellitus93.  
Expected losses in chromosomes 1 and 11 were present in our cohort but 
insignificant in recurrence as were losses in 2 and 18. Recurrent copy number 
gains were identified in chromosomes 7 and 14 without significance as were 
losses in 15. Variations in chromosome 4 were present, again without 
significance. Significant copy number losses in chromosome 10 were identified, 
particularly in SCAs, suggesting a role in non-functioning pituitary adenoma 
growth.  
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DISCUSSION 
 
Recent insights into the molecular stratification of pituitary adenomas 
enforce the importance of genomic characterization of these tumors26. Next 
generation sequencing using an OncoPanel assay has improved the ease and 
accuracy of genomic profiling as a diagnostic method, demonstrating an ability to 
predict treatment outcomes and likely disease progression, further elucidating the 
potentials of molecular profiling29,94,95. Our study sought to identify potential 
genetic drivers of pituitary corticotroph adenomas and to differentiate between 
the genomic variant profiles of phenotypic subtypes. The cohort of this study was 
relatively small and limited by the number of genes screened in each assay. 
While recurrent variants in corticotroph adenomas were detected, these results 
should be interpreted with caution and require additional validation. 
We report genomic disruption as an important differentiator between two 
distinct classes of sporadic corticotroph adenomas. Moreover, we were able to 
loosely correlate a lower degree of disruption with potential USP8 mutations in 
FCAs. This association revealed incomplete penetrance, with only half of the 
samples containing a USP8 mutations showing significantly reduced disruption. 
Silent and functional corticotroph adenomas were stratified by copy number 
profile, highlighting the relationship between disruption and hormone-secreting 
function. While 16.7% (2 of 12) of FCAs were found to have low to moderate 
disruption, all of the SCA subjects showed a high level of genomic disruption, 
consistent with previously validated findings26. Additionally, we demonstrated the 
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similarity between corticotroph hyperplasia and FCAs. Our two CH subjects had 
a similarly disrupted genomic profile to FCAs not bearing a mutation in USP8, 
and both groups resulted in hypercortisolism prior to tumor resection and tissue 
collection. These results emphasize the role of genomic disruption in CD and 
tumor behavior, especially as it relates to pathological hormone elevation. 
The identification of chromosomal rearrangements in ACTH secreting 
subgroups, FCA and CH, further implicate susceptible regions in CD 
development. While silent corticotroph adenomas seem to result from an 
accumulation of genomic instability, functional adenomas and hyperplasia are 
more likely to result from a few key mutations or structural changes within 
chromosomal regions of interest. While there were no significant regions 
identified in this study, further investigation may identify structural variations 
aiding in corticotroph tumor formation. 
We identified differential variations of copy number between the two 
adenoma subgroups. Copy number gains occurred more frequently in FCAs as 
compared to SCAs suggesting amplification of certain chromosomal regions 
result in hormonal hypersecretion. Significant amplification of 21q, associated 
with Down syndrome, suggests this region may contribute to some of the 
developmental delays and physical characteristics of CD. U2AF1, a 
housekeeping gene found in this region, has been suggested to inhibit the p53 
signaling pathway resulting in specific phenotypes characterized by 
neurodevelopmental delays in previous studies on embryo development96. 
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Chromosomes 6p and 20q, both amplified in FCAs, have been suggested as 
regions involved in functional tumor hormone secretion. While variations of 6p 
were also identified in SCA, these were almost entirely copy number loss, further 
stressing the role of this chromosome in FCA hormone secretion. The majority of 
the genes significantly altered in this region were epigenetic regulators involved 
in DNA transcription. Furthermore, GNAS, found on 20q, has been identified as a 
genetic driver of growth hormone secreting pituitary tumors and are implicated in 
prolactinoma tumor formation as well. Although no genetic mutations of GNAS 
were identified in this study, we propose amplification of this gene in FCAs, 
similar to gain-of-function mutations in somatotrophomas, enhances hormone 
secretion and tumor growth.  
Two regions of significant loss were identified in FCAs, 11p and 19q. 
Losses in 11p relate to pituitary tumor aggressiveness, particularly in 
prolactinomas97,98. The relation of 11p loss to prolactinomas is reminiscent of the 
role of GNAS amplification in this same pituitary tumor type. Moreover, single 
copy deletions of AXL, found in 19q are associated with hypogonadotropic 
hypogonadism during development suggesting an inverse role to GNAS in 
relation to growth hormone secretion99. Allelic copy number deletions of CBL 
predominantly seen in SCAs corresponded to expected copy number gains in 
AXL as well as amplifications of Axl’s downstream targets within our SCA sample 
population. These findings suggest increased Axl signaling decreases hormone 
secretion while reduced Axl signaling enhances secretion. The variable copy 
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number change of AXL in FCA versus SCA samples as well as the correlated 
copy number variations in genes involved in the Axl signaling pathway make AXL 
an additional target for future studies.  
Amplification of chromosome 12 regions associated with cell cycle 
progression and transcription regulation occurred with significant frequency in 
SCA. Associated copy number gains of CDKN1B, found in 80% of SCA samples, 
may have a similar inverse relationship to hormone secretion as AXL. Loss-of-
function germline mutations in this gene are commonly found in MEN4 
associated somatotrophinomas, suggesting inhibitory regulation of hormone 
secretion through p2735. Moreover, p27 acts as an inhibitor of cell cycle 
progression within the pituitary gland and prevents ACTH secretion in 
corticotroph adenomas, as illustrated in Figure 1. Additional study of this gene 
would be required to elucidate a more concrete role in SCA formation. 
Amplification of 12q was also commonly found in SCA samples within our study 
and has previously been identified in a subset of neuroblastomas suggesting a 
role in tumorigenesis92. Of importance, genes associated with other MEN 
syndrome phenotypes, including MEN1, as well as RET and WT1, found on 12q, 
were commonly varied in our adenoma cohort, exemplifying the close connection 
between multiple endocrine neoplasia and pituitary adenoma formation. 
We further identified significant recurrence of allelic losses on 
chromosome 10 within our SCA subjects. Copy number loss of 10q is associated 
with aggressiveness in tumor invasion within pituitary adenomas while 10p is 
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involved in the development of gliomas as well as the progression to 
malignancy100,101. Chromosome 10 may house genes responsible for the invasive 
nature of the silent corticotroph subtype or for the rapid cellular proliferation and 
large adenoma size seen in SCA. 
 Three unique variants targeted to the 14-3-3 binding domain of USP8 
were identified in our study. As predicted based on previous research and 
literature review, all variants occurred within this region of USP8. These SNPs 
resulted in a USP8 gain of function leading to increased deubiquitination of 
EGFR and thus increased ACTH production and secretion in functional 
adenomas. Mutations in USP8 were identified in 4 of the 6 functional adenomas 
screened for the gene with OncoPanel version 3. Of the 4 FCAs with a mutation 
contained in the ARID1B gene, only one sample was screened for USP8. This 
subject, assayed for variants in USP8 and ARID1B, had mutations in both genes. 
Future studies will screen for USP8 and ARID1B mutations in order to determine 
if there is a relationship between these two genes in FCAs. No SNPs in either of 
these genes were identified in SCA, solidifying their phenotypic role in functional 
adenomas. 
Within ARID1B, we described three unique variants of unknown 
significance as well as variant ARID1BA931T which has been established as a rare 
loss of function mutation in large intestine adenocarcinomas. A link between 
pituitary tumors and the enteric nervous system may be implicated. Importantly, 
ARID1BA931T was altered in a subject containing an additional mutation in 
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ARID1A likely resulting in the elimination of the SWI/SNF complex resulting in 
cellular destabilization. The combination of functional loss in these chromatin 
remodeling factors has been identified in neuroblastoma formation and can occur 
in both cancer cell lines as well as primary tumors38. A secondary mutation 
inhibiting cellular apoptosis is likely required to promote cellular propagation in 
this particular tumor. Further analysis of the novel variants identified by our study 
showed additional losses of function through frameshift mutations. Although 
ARID1BM1248V was classified as benign after sequential and structural analysis of 
the resulting protein, it is difficult to predict the effect this mutation would have on 
protein and cellular function. The evolutionary preservation of the amino acid, 
Met, within the ARID1B protein sequence suggests a potentially damaging 
alteration. Because copy number gains of additional SWI/SNF complex subunits 
including ARID1B were identified in SCAs and not in FCAs, while loss of function 
SNPs were only present in FCAs, loss of histone ubiquitination likely plays a role 
in tumor behavior and phenotypic presentation. Of significance, no alterations 
were found within the ARID DNA binding domain of ARID1B or within the domain 
of unknown function, suggesting ARID1B maintains its ability to bind to DNA 
without enzymatic function. A map of variant locations can be seen in Figure 4. 
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Figure 4: Location of SNPs on USP8 and ARID1B. 
a) The location of 3 variants identified in USP8 within the 14-3-3 binding domain. 
Variant USP8S719del was found in two subjects but is only shown once in this 
image. b) The location of 4 variants within the ARID1B gene. No specific region 
was prone to mutation in this gene. c) Diagram depicting SWI/SNF complex 
destabilization following ARID1B loss of function.  
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In future studies, we plan to perform an assay of tumor tissue and 
matched blood samples collected from a larger cohort of patients who have 
undergone surgery at Brigham and Woman’s Hospital for resection of a 
diagnosed corticotroph pituitary tumor in order to validate corticotroph adenoma 
genetic drivers by subtype. We will attempt to identify copy number variations 
and mutations in GNAS in order to elucidate the gene’s role in tumorigenesis and 
ACTH hormone secretion. Because amplification of this gene was identified in 
60.0% (3 of 5) of SCAs, we will compare tumor invasion, size and function to the 
presence of GNAS copy number variations. Additionally, AXL will be assayed for 
copy number variations in order to assess the role of this signaling pathway in 
hormone secretion and tumor function as there seems to be a correlation 
between gene amplification and disruption of hormone secretion. We may also 
choose to examine copy number changes in PTPN11 and CBL to further 
highlight the potential implications of this pathway in corticotrophic subtype 
differentiation. CDKN1B will be included in this assay as well. Loss of function 
mutations in this gene have been cited in non-ACTH secreting pituitary subtypes, 
but an amplification of CDKN1B seems to be involved in SCA formation or 
function. We plan to perform whole exome sequencing to screen for variants and 
copy number changes in additional genes implicated in MEN syndrome. 
Alongside analysis of copy number variations, we hope to further examine 
the presence and functional changes of SNPs in our upcoming studies. Particular 
interest will be paid to ARID1B, as USP8 has already been validated as playing a 
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part in functional corticotroph tumorigenesis by previous studies. We will 
additionally examine both copy number changes and mutations found in genes of 
interest, principally those genes with recurrent SNPs identified in our preliminary 
study. CABLES1 will be added to the list of genes we will review, as we were 
unable to analyze this gene in the current investigation. A gain of function 
mutation in CABLES1 has been shown to amplify p27 expression, possibly 
producing an adenoma phenotype similar to CDKN1B amplified tumors. This 
information would further solidifying the role of CDKN1B amplification in SCA 
functioning. 
Moreover, our study highlights several candidate regulatory genes that 
require supplementary investigation and pathological characterization in 
corticotroph adenomas specifically. Examples of nuclear epigenetic regulators 
within our cohort involved in adenoma pathogenesis through histone acetylation 
activity include BRCA2, KAT6A, EP300 and TP53/BP1. Contextual exploration of 
epigenetic mechanisms in corticotroph adenomas must be done to establish their 
mutational status. Considering the high frequency of alterations in epigenetic 
regulators within the pituitary corticotroph adenoma population we studied, 
targeting these epigenetic mechanisms may provide a therapeutic treatment for 
these tumors. Currently the only FDA-approved therapies targeting epigenetic 
modulation are histone deacetylase inhibitors and DNA methyltransferase 
inhibitors102. Histone deacetylase inhibitors have been patented for use in 
neuroendocrine tumors; however, their efficacy in the treatment of pituitary 
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adenomas is still being studied103. Because FCAs presented in our study with 
more variation in genes required for histone methylation modification than SCAs, 
DNA methyltransferase inhibitors may be more effective in this subtype of 
corticotroph adenoma.  
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APPENDIX 1 
List of 447 genes screened in OncoPanel version 3: 
ABCB11, ABL1, ACVR1, AKT1, AKT2, AKT3, ALK, APC, AR, ARAF, 
ARHGAP35, ARHGEF12, ARID1A, ARID1B,  ARID2, ASXL1, ATM, ATR, ATRX, 
AURKA, AURKB, AXIN2, AXL 
B2M, BABAM1, BAP1, BARD1, BCL11B, BCL2, BCL2L1, BCL2L12, BCL6, 
BCOR, BCORL1, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRCC3, BRD3, 
BRD4, BRE, BRIP1, BUB1B 
C17ORF70, C19ORF40, C1ORF86, CALR, CARD11, CASP8, CBFA2T3, CBFB, 
CBL, CBLB, CCND1, CCND2, CCND3, CCNE1, CD274, CD79B, CDC73, CDH1, 
CDH4, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN1C, CDKN2A, 
CDKN2B, CDKN2C, CEBPA, CHEK1, CHEK2, CIC, CIITA, COL7A1, CREBBP, 
CRKL, CRLF2, CRTC1, CSF3R, CTCF, CTLA4, CTNNA1, CTNNB1, CUX1, 
CXCR4, CYLD 
DAXX, DCLRE1C, DDB1, DDB2, DDR2, DICER1, DIS3, DIS3L2, DKC1, DMC1, 
DNMT3A, DOCK8 
EGFR, EGLN1, ELANE, EME1, ENG, EP300, EPCAM, ERBB2, ERBB3, ERBB4, 
ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, ERG, ESR1, ETV1, ETV4, 
ETV5, ETV6, EWSR1, EXO1, EXT1, EXT2, EZH2 
FAH, FAM175A, FAM46C, FAN1, FANCA, FANCB, FANCC, FANCD2, FANCE, 
FANCF, FANCG, FANCI, FANCL, FANCM, FAS, FAT1, FBXW7, FGFR1, 
FGFR2, FGFR3, FGFR4, FH, FLCN, FLT1, FLT3, FLT4, FOXA1, FOXL2, FUS 
GALNT12, GATA2, GATA3, GATA4, GATA6, GBA, GEN1, GLI1, GLI2, GNA11, 
GNAQ, GNAS, GPC3, GREM1 
H19, H3F3A, H3F3B, HABP2, HELQ, HFE, HIST1H3B, HIST1H3C, HMBS, 
HNF1A, HOXB13, HRAS 
ID3, ID4, IDH1, IDH2, IGF1R, IGF2, IKZF1, IL7R, ITK 
JAK1, JAK2, JAK3, JAZF1 
KAT6A, KAT6B, KCNQ1, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KIF1B, KIT, 
KLF2, KLF4, KLLN, KMT2A, KMT2D, KRAS 
LIG4, LMO1, LMO2 
MAF, MAFB, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAPK1, MAX, MBD4, 
MCL1, MCM8, MDM2, MDM4, MECOM, MED12, MEF2B, MEN1, MET, MGA, 
MITF, MLH1, MLH3, MPL, MRE11A, MSH2, MSH6, MTA1, MTAP, MTOR, 
MUS81, MUTYH, MYB, MYBL1, MYC, MYCL1, MYCN, MYD88 
NBN, NEIL1, NEIL2, NEIL3, NF1, NF2, NFE2L2, NFKBIA, NFKBIE, NFKBIZ, 
NKX2-1, NKX3-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NR0B1, NRAS, NRG1, 
NSD1, NT5C2, NTHL1, NTRK1, NTRK2, NTRK3 
OGG1 
PALB2, PARK2, PAX5, PAXIP1, PBRM1, PDCD1LG2, PDGFRA, PDGFRB, 
PHF6, PHOX2B, PIK3C2B, PIK3CA, PIK3R1, PIM1, PML, PMS1, PMS2, PNKP, 
POLB, POLD1, POLE, POLH, POLQ, POT1, PPARG, PPM1D, PPP2R1A, 
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PRDM1, PRF1, PRKAR1A, PRKCI, PRKDC, PRSS1, PTCH1, PTEN, PTK2B, 
PTPN11, PTPN14, PVRL4 
QKI 
RAC1, RAD21, RAD50, RAD51, RAD51C, RAD51D, RAD52, RAD54B, RAF1, 
RARA, RASA1, RB1, RBBP8, RBM10, RECQL4, REL, RELA, RET, RHBDF2, 
RHEB, RHOA, RHOH, RHOT1, RICTOR, RIF1, RINT1, RIT1, RMRP, RNF43, 
RNF8, ROS1, RPA1, RPTOR, RSPO2, RSPO3, RUNX1, RUNX1T1 
SBDS, SDHA, SDHAF2, SDHB, SDHC, SDHD, SERPINA1, SETBP1, SETD2, 
SF3B1, SH2B3, SH2D1A, SLC25A13, SLC34A2, SLX1A, SLX1B, SLX4, 
SMAD2, SMAD4, SMARCA4, SMARCB1, SMARCE1, SMC3, SMO, SOCS1, 
SOS1, SOX2, SOX9, SPOP, SRSF2, SRY, SS18, STAG2, STAT3, STAT6, 
STK11, SUFU, SUZ12 
TAL1, TAL2, TAZ, TCEB1, TCF3, TCF7L2, TDG, TERC, TERT, TET1, TET2, 
TFE3, TLX3, TMEM127, TMPRSS2, TNFAIP3, TOPBP1, TP53, TP53BP1, 
TRAF3, TRAF7, TRIM37, TSC1, TSC2, TSHR 
U2AF1, UBE2T, UIMC1, UROD, USP28, USP8 
VEGFA, VHL 
WAS, WHSC1, WHSC1L1, WRN, WT1 
XPA, XPC, XPO1, XRCC1, XRCC2, XRCC3, XRCC4, XRCC5, XRCC6 
YAP1 
ZNF217, ZNRF3, ZRSR2 
 
List of 300 genes screened in OncoPanel version 2: 
ABL1, AKT1, AKT2, AKT3, ALK, ALOX12B, APC, AR, ARAF, ARID1A, ARID1B, 
ARID2, ASXL1, ATM, ATRX, AURKA, AURKB, AXL 
B2M, BAP1, BCL2, BCL2L1, BCL2L12, BCL6, BCOR, BCORL1, BLM, BMPR1A, 
BRAF, BRCA1, BRCA2, BRD4, BRIP1, BUB1B 
CADM2, CARD11, CBL, CBLB, CCND1, CCND2, CCND3, CCNE1, CD274, 
CD58, CD79B, CDC73, CDH1, CDK1, CDK2, CDK4, CDK5, CDK6, CDK9, 
CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2B, CDKN2C, CEBPA, CHEK2, 
CIITA, CREBBP, CRKL, CRLF2, CRTC1, CRTC2, CSF1R, CSF3R, CTNNB1, 
CUX1, CYLD 
DDB2, DDR2, DEPDC5, DICER1, DIS3, DMD, DNMT3A 
EED, EGFR, EP300, EPHA3, EPHA5, EPHA7, ERBB2, ERBB3, ERBB4, 
ERCC2, ERCC3, ERCC4, ERCC5, ESR1, ETV1, ETV4, ETV5, ETV6, EWSR1, 
EXT1, EXT2, EZH2 
FAM46C, FANCA, FANCC,FANCD2, FANCE, FANCF, FANCG, FAS, FBXW7, 
FGFR1, FGFR2, FGFR3, FGFR4, FH, FKBP9, FLCN, FLT1, FLT3, FLT4, FUS 
GATA3, GATA4, GATA6, GLI1, GLI2, GLI3, GNA11, GNAQ, GNAS, GNB2L1, 
GPC3, GSTM5 
H3F3A, HNF1A, HRAS 
ID3, IDH1, IDH2, IGF1R, IKZF1, IKZF3, INSIG1 
JAK2, JAK3 
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KCNIP1, KDM5C, KDM6A, KDM6B, KDR, KEAP1, KIT, KRAS 
LINC00894, LMO1, LMO2, LMO3 
MAP2K1, MAP2K4, MAP3K1, MAPK1, MCL1, MDM2, MDM4, MECOM, MEF2B, 
MEN1, MET, MITF, MLH1, MLL, MLL2, MPL, MSH2, MSH6, MTOR, MUTYH, 
MYB, MYBL1, MYC, MYCL1, MYCN, MYD88 
NBN, NEGR1, NF1, NF2, NFE2L2, NFKBIA, NFKBIZ, NKX2-1, NOTCH1, 
NOTCH2, NPM1, NPRL2, NPRL3, NRAS, NTRK1, NTRK2, NTRK3 
PALB2, PARK2, PAX5, PBRM1, PDCD1LG2, PDGFRA, PDGFRB, PHF6, 
PHOX2B, PIK3C2B, PIK3CA, PIK3R1, PIM1, PMS1, PMS2, PNRC1, PRAME, 
PRDM1, PRF1, PRKAR1A, PRKCI, PRKCZ, PRKDC, PRPF40B, PRPF8, 
PSMD13, PTCH1, PTEN, PTK2, PTPN11, PTPRD 
QKI 
RAD21, RAF1, RARA, RB1, RBL2, RECQL4, REL, RET, RFWD2, RHEB, 
RHPN2, ROS1, RPL26, RUNX1 
SBDS, SDHA, SDHAF2, SDHB, SDHC, SDHD, SETBP1, SETD2, SF1, SF3B1, 
SH2B3, SLITRK6, SMAD2, SMAD4, SMARCA4, SMARCB1, SMC1A, SMC3, 
SMO, SOCS1, SOX2, SOX9, SQSTM1, SRC, SRSF2, STAG1, STAG2, STAT3, 
STAT6, STK11, SUFU, SUZ12, SYK 
TCF3, TCF7L1, TCF7L2, TERC, TERT, TET2, TLR4, TNFAIP3, TP53, TSC1, 
TSC2 
U2AF1 
VHL 
WRN, WT1 
XPA, XPC, XPO1 
ZNF217, ZNF708, ZRSR2 
 
List of 471 loci on 41 genes screened in OncoMap version 1: 
 
ABL1_E355G, ABL1_F359V, ABL1_G250E, ABL1_H396R, ABL1_M244V, 
ABL1_M351T, ABL1_Q252H, ABL1_Y253F, APC_E1309fs*6, APC_Q1367*, 
APC_Q1378*, APC_Q1429*, APC_R1114*, APC_T1556fs*3 
BRAF_D587A, BRAF_D587E, BRAF_E586K, BRAF_G464E, BRAF_G466A, 
BRAF_G466E, BRAF_G466V, BRAF_G469E, BRAF_R444W 
CDK4_R24H, CDKN2A_D84Y, CDKN2A_E61*, CDKN2A_E69*, 
CDKN2A_P114L, CSF1R_L301*, CSF1R_L301S, CSF1R_Y969*, 
CSF1R_Y969*, CSF1R_Y969F, CTNNB1_A21T, CTNNB1_G34R, 
CTNNB1_G34R, CTNNB1_S37A, CTNNB1_S37P 
EGFR_D761N, EGFR_D761Y, EGFR_D770_N771insN, EGFR_G719A, 
EGFR_G719C, EGFR_G719D, EGFR_S752_I759del, EGFR_G719S, 
EGFR_G810S, EGFR_H773R, EGFR_L730F, EGFR_N771_P772>SVDNR, 
EGFR_P733L, ERBB2_V777L 
FGFR1_P252T, FGFR1_S125L, FGFR2_C382R, FGFR2_K310R, 
FGFR2_N549K, FGFR2_Y375C, FGFR3_G697C, FGFR3_K650Q, 
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FGFR3_L794fs*23, FGFR3_R248C, FGFR3_S371C, FGFR3_Y373C, 
FLT3_D835E, FLT3_D835V, FLT3_Y572C 
GNAQ_Q209L, GNAQ_Q209P, GNAS_R201H, HRAS_G12V, HRAS_G13V 
HRAS_Q61H 
JAK3_A572V, JAK3_P132T, JAK3_V722I 
KIT_D816V, KIT_E839K, KIT_K550_K558del, KIT_K558_E562del, KIT_N822K, 
KIT_N822K, KIT_V560G, KIT_W557R, KIT_W557R, KIT_Y503_F504insAY, 
KIT_P585P, KIT_V559A, KIT_V559D, KIT_V559del, KIT_V559G, KIT_V560D, 
KRAS_A146T, KRAS_A59T, KRAS_G13R, KRAS_G13S, KRAS_Q22K 
MAP2K1_C121S, MAP2K1_D67N, MAP2K1_K57N, MAP2K1_P124L, 
MET_H1112Y, MET_M1268T, MET_Y1248C, MET_Y1248H, MYC_P260A 
NRAS_A18T, NRAS_Q61H, NRAS_Q61R 
PDGFRA_D842_D846>E, PDGFRA_D842_S847>EA, PDGFRA_D846Y, 
PDGFRA_H845_N848>P, PDGFRA_I843_D846del, PDGFRA_R841_D842del, 
PDGFRA_S566_E571>K, PDGFRA_S566_E571>R, PDGFRA_V561D, 
PIK3CA_E545G, PIK3CA_E545Q, PIK3CA_G1049R, PIK3CA_G1049S, 
PIK3CA_M1043I, PIK3CA_M1043I, PIK3CA_N1068fs*4, PIK3CA_Y1021C, 
PIK3R1_D560_S565del, PIK3R1_E439del, PIK3R1_G376R, PIK3R1_G376R, 
PIK3R1_K459_S460>N,PIK3R1_R461*, PIK3R1_R557_K561>Q, 
PTEN_K267fs*9, PTEN_K6fs*4, PTEN_R130*, PTEN_R173C, PTEN_R173H, 
PTEN_V317fs*3 
RB1_C706F, RB1_E137*, RB1_E748*, RB1_L199*, RB1_L660fs*2, RB1_R320*, 
RB1_R358*, RB1_R552*, RB1_R579*, RET_A883F, RET_A883F, RET_C634R, 
RET_C634Y 
STK11_D194N, STK11_D194V, STK11_E57fs*7, STK11_F264fs*22, 
STK11_G196V, STK11_P281fs*6, STK11_P281L, STK11_Q170*, STK11_Q37* 
TP53_R273H 
VHL_L158Q , VHL_L85P, VHL_R161* 
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APPENDIX 2 
Genetic abbreviations defined. 
 
Abbreviation Definition 
AIP Aryl Hydrocarbon Receptor Interacting Protein 
ARID1A AT-Rich Interaction Domain 1A 
ARID1B AT-Rich Interaction Domain 1B 
ARID2 AT-Rich Interaction Domain 2 
ASXL1 ASXL Transcriptional Regulator 1 
ATM ATM Serine/Threonine Kinase 
AXL AXL Receptor Tyrosine Kinase 
BRCA1 BRCA1, DNA Repair Associated 
BRCA2 BRCA2, DNA Repair Associated 
BRD4 Bromodomain-Containing Protein 4 
CABLES1 Cdk5 and Abl Enzyme Substrate 1 
CCND2 Cyclin D2 
CCND3 Cyclin D3 
CDK4 Cyclin Dependent Kinase 4 
CDKN1A Cyclin Dependent Kinase Inhibitor 1A 
CDKN1B Cyclin Dependent Kinase Inhibitor 1B 
CREBBP CREB Binding Protein 
CRHR1 Corticotropin Releasing Hormone Receptor 1 
EGFR Epidermal Growth Factor Receptor 
EP300 E1A Binding Protein P300 
ERBB3 Erb-B2 Receptor Tyrosine Kinase 3 
ERBB4 Erb-B2 Receptor Tyrosine Kinase 4 
ETV6 ETS Variant 6 
FANCA Fanconi Anemia Complementation Group A 
FANCE Fanconi Anemia Complementation Group E 
FBXW7 F-Box and WD Repeat Domain Containing 7 
GATA3 GATA Binding Protein 3 
GLI1 GLI Family Zinc Finger 1 
GLI2 GLI Family Zinc Finger 2 
GLI3 GLI Family Zinc Finger 3 
GNAS GNAS Complex Locus 
GPR101 G Protein-Coupled Receptor 101 
HNF1A HNF1 Homeobox A 
KAT6A Lysine Acetyltransferase 6A 
KMT2D Lysine Methyltransferase 2D 
KRAS Kirsten Rat Sarcoma 2 Viral Oncogene Homolog 
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MDM2 Mouse Double Minute 2 Homolog 
MEN1 Multiple Endocrine Neoplasia 1 
NF2 Neurofibromatosis Type 2 
NOTCH1 Neurogenic Locus Notch Homolog Protein 1 
NOTCH2 Neurogenic Locus Notch Homolog Protein 2 
PCV3 Porcine Circovirus 3 
PIK3CA 
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic 
Subunit Alpha 
PIM1 Proto-Oncogene Serine/Threonine Protein Kinase 
POMC Proopiomelanocortin 
PRKAR1A Protein Kinase cAMP-Dependent Regulatory Type 1 Alpha 
PRKDC Protein Kinase DNA-Activated Catalytic Subunit 
PTPN11 Protein Tyrosine Phosphatase Non-Receptor Type 11 
RET Ret Proto-Oncogene 
SDHx Succinate Dehydrogenase Complex Iron Sulfur 
SH2B3 SH2B Adaptro Protein 3 
SMARCA4 SWI/SNF Related Matrix Associated Actin Dependent 
Regulator of Chromatin Subfamily A Member 4 
SMARCB1 SWI/SNF Related Matrix Associated Actin Dependent 
Regulator of Chromatin Subfamily B Member 1 
SSTR1 Somatostatin Receptor 1 
SSTR2 Somatostatin Receptor 2 
STAT6 Signal Transducer and Activator of Transcription 6 
TP53 Tumor Protein P53 
TP53BP1 Tumor Protein P53 Binding Protein 1 
U2AF1 U2 Small Nuclear RNA Auxiliary Factor 1 
USP8 Ubiquitin Specific Peptidase 8 
V1BR Vasopressin Receptor 1B 
WT1 Wilms Tumor Protein  
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